Full Text Journal Articles by
Author Brian C Betts

Advertisement

Find full text journal articles






Clarifying the translational potential of B-I09.

Juan R Del Valle, Brian C Betts, Xue-Zhong Yu, Sophie Janssens, Bart N Lambrecht, M Celeste Simon, Chih-Chi Andrew Hu,

Nat Chem Biol (Nature chemical biology)
[2020, 16(11):1152]

Cited: 0 times

View full text PDF listing >>



Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.

Bishwas Shrestha, Kelly Walton, Jordan Reff, Elizabeth M Sagatys, Nhan Tu, Justin Boucher, Gongbo Li, Tayyebb Ghafoor, Martin Felices, Jeffrey S Miller, Joseph Pidala, Bruce R Blazar, Claudio Anasetti, Brian C Betts, Marco L Davila,

Graft-versus-host disease (GVHD) remains an important cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). For decades, GVHD prophylaxis has included calcineurin inhibitors, despite their incomplete efficacy and impairment of graft-versus-leukemia (GVL). Distinct from pharmacologic immune suppression, we have developed what we believe is a novel, human CD83-targeted ... Read more >>

J. Clin. Invest. (The Journal of clinical investigation)
[2020, 130(9):4652-4662]

Cited: 0 times

View full text PDF listing >>



Advertisement

Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity.

Kelly Walton, Mario R Fernandez, Elizabeth M Sagatys, Jordan Reff, Jongphil Kim, Marie Catherine Lee, John V Kiluk, Jane Yuet Ching Hui, David McKenna, Meghan Hupp, Colleen Forster, Michael A Linden, Nicholas J Lawrence, Harshani R Lawrence, Joseph Pidala, Steven Z Pavletic, Bruce R Blazar, Said M Sebti, John L Cleveland, Claudio Anasetti, Brian C Betts,

Immunosuppressive donor Tregs can prevent graft-versus-host disease (GVHD) or solid-organ allograft rejection. We previously demonstrated that inhibiting STAT3 phosphorylation (pSTAT3) augments FOXP3 expression, stabilizing induced Tregs (iTregs). Here we report that human pSTAT3-inhibited iTregs prevent human skin graft rejection and xenogeneic GVHD yet spare donor antileukemia immunity. pSTAT3-inhibited iTregs express ... Read more >>

JCI Insight (JCI insight)
[2020, 5(9):]

Cited: 0 times

View full text PDF listing >>



Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host Disease.

Chiara Frairia, Maura Nicolosi, Jamie Shapiro, Jongphil Kim, Brian C Betts, Hugo F Fernandez, Frederick L Locke, Asmita Mishra, Taiga Nishihori, Jose Leonel Ochoa-Bayona, Lia Perez, Joseph Pidala, Claudio Anasetti,

Systemic glucocorticoids remain the standard treatment for gastrointestinal (GI) acute graft-versus-host disease (aGVHD) despite their toxicity and incomplete efficacy. Controlled trials have tested poorly absorbable steroids as adjuncts with systemic glucocorticoids, but only small case series have reported treatment with poorly absorbed beclomethasone dipropionate (BDP) and budesonide (BUD) alone. Our ... Read more >>

Biol. Blood Marrow Transplant. (Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation)
[2020, 26(7):1303-1311]

Cited: 0 times

View full text PDF listing >>



Editorial: Pathogenesis and Therapy of Graft-versus-Host Disease.

Brian C Betts, Xue-Zhong Yu,

Front Immunol (Frontiers in immunology)
[2019, 10:1797]

Cited: 0 times

View full text PDF listing >>



Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease.

Shernan G Holtan, Ashraf Shabaneh, Brian C Betts, Armin Rashidi, Margaret L MacMillan, Celalletin Ustun, Khalid Amin, Byron P Vaughn, Justin Howard, Alexander Khoruts, Mukta Arora, Todd E DeFor, Darrell Johnson, Bruce R Blazar, Daniel J Weisdorf, Jinhua Wang,

Steroid-refractory intestinal acute graft-versus-host disease (aGVHD) is a frequently fatal condition with little known about mechanisms driving failed steroid responses in gut mucosa. To uncover novel molecular insights in steroid-refractory aGVHD, we compared gene expression profiles of rectosigmoid biopsies from patients at diagnosis of clinical stage 3-4 lower intestinal aGVHD ... Read more >>

JCI Insight (JCI insight)
[2019, 5:]

Cited: 1 time

View full text PDF listing >>



The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease.

David Bastian, Yongxia Wu, Brian C Betts, Xue-Zhong Yu,

Allogeneic hematopoietic cell transplantation (allo-HCT) is performed with curative intent for high- risk blood cancers and bone marrow failure syndromes; yet the development of acute and chronic graft-vs.-host disease (GVHD) remain preeminent causes of death and morbidity. The IL-12 family of cytokines is comprised of IL-12, IL-23, IL-27, IL-35, and ... Read more >>

Front Immunol (Frontiers in immunology)
[2019, 10:988]

Cited: 3 times

View full text PDF listing >>



Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.

Brian C Betts, Frederick L Locke, Elizabeth M Sagatys, Joseph Pidala, Kelly Walton, Meghan Menges, Jordan Reff, Asim Saha, Julie Y Djeu, John V Kiluk, Marie C Lee, Jongphil Kim, Chang Won Kang, Chih-Hang Tang, Jeremy Frieling, Conor C Lynch, Alan List, Paulo C Rodriguez, Bruce R Blazar, Jose R Conejo-Garcia, Juan R Del Valle, Chih-Chi Hu, Claudio Anasetti,

Acute graft- vs. -host disease (GVHD) is an important cause of morbidity and death after allogeneic hematopoietic cell transplantation (HCT). We identify a new approach to prevent GVHD that impairs monocyte-derived dendritic cell (moDC) alloactivation of T cells, yet preserves graft- vs.-leukemia (GVL). Exceeding endoplasmic reticulum (ER) capacity results in ... Read more >>

Front Immunol (Frontiers in immunology)
[2018, 9:2887]

Cited: 6 times

View full text PDF listing >>



Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.

David M Woods, Rupal Ramakrishnan, Andressa S Laino, Anders Berglund, Kelly Walton, Brian C Betts, Jeffrey S Weber,

PURPOSE:PD-1 blockade induces durable responses in patients with metastatic melanoma and prolongs relapse-free survival in patients with resected melanoma; however, current biomarkers do not consistently associate with patient responses. In this study, we investigated the impact of nivolumab therapy on peripheral blood regulatory T cells (Treg) and its relation to ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2018, 24(24):6236-6247]

Cited: 9 times

View full text PDF listing >>



Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease.

Kelli P A MacDonald, Brian C Betts, Daniel Couriel,

Biol. Blood Marrow Transplant. (Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation)
[2018, 24(3S):S7-S14]

Cited: 2 times

View full text PDF listing >>



Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.

Brian C Betts, David Bastian, Supinya Iamsawat, Hung Nguyen, Jessica L Heinrichs, Yongxia Wu, Anusara Daenthanasanmak, Anandharaman Veerapathran, Alison O'Mahony, Kelly Walton, Jordan Reff, Pedro Horna, Elizabeth M Sagatys, Marie C Lee, Jack Singer, Ying-Jun Chang, Chen Liu, Joseph Pidala, Claudio Anasetti, Xue-Zhong Yu,

Janus kinase 2 (JAK2) signal transduction is a critical mediator of the immune response. JAK2 is implicated in the onset of graft-versus-host disease (GVHD), which is a significant cause of transplant-related mortality after allogeneic hematopoietic cell transplantation (allo-HCT). Transfer of JAK2-/- donor T cells to allogeneic recipients leads to attenuated ... Read more >>

Proc. Natl. Acad. Sci. U.S.A. (Proceedings of the National Academy of Sciences of the United States of America)
[2018, 115(7):1582-1587]

Cited: 14 times

View full text PDF listing >>



Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score.

Mohamed A Kharfan-Dabaja, Kyle Sheets, Ambuj Kumar, Hemant S Murthy, Taiga Nishihori, Athanasios Tsalatsanis, Alain Mina, John Mathews, Ernesto Ayala, Julio Chavez, Lia E Perez, Brian C Betts, Claudio Anasetti, Joseph Pidala,

Hypoalbuminaemia has been previously described to predict worse non-relapse mortality (NRM) and inferior overall survival (OS) in allogeneic haematopoietic cell transplant (allo-HCT) recipients. Here, we evaluate the role of hypoalbuminaemia (<35 g/l) at time of onset of acute graft-versus-host disease (aGVHD) when incorporated into the refined aGVHD score. The study population ... Read more >>

Br. J. Haematol. (British journal of haematology)
[2018, 180(6):854-862]

Cited: 0 times

View full text PDF listing >>



Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease.

Kelli P A MacDonald, Brian C Betts, Daniel Couriel,

Biol. Blood Marrow Transplant. (Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation)
[2018, 24(1):19-26]

Cited: 3 times

View full text PDF listing >>



Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.

Hemant S Murthy, Kyle Sheets, Ambuj Kumar, Taiga Nishihori, Alain Mina, Julio C Chavez, Ernesto Ayala, Teresa Field, John Mathews, Frederick Locke, Lia Perez, Brian C Betts, Farhad Khimani, Branco Miladinovic, Athanasios Tsalatsanis, Jose Leonel Ochoa-Bayona, Melissa Alsina, Hugo Fernandez, Joseph Pidala, Claudio Anasetti, Mohamed A Kharfan-Dabaja,

Prognostic biomarkers in allogeneic hematopoietic cell transplantation (allo-HCT) are needed to improve risk assessment and help guide therapeutic and surveillance strategies to mitigate the risk of death from the procedure. We previously identified hypoalbuminemia at day +90 post-transplantation as an independent predictor of increased nonrelapse mortality (NRM) and inferior overall ... Read more >>

Biol. Blood Marrow Transplant. (Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation)
[2018, 24(2):400-405]

Cited: 0 times

View full text PDF listing >>



IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.

Brian C Betts, Joseph Pidala, Jongphil Kim, Asmita Mishra, Taiga Nishihori, Lia Perez, Jose Leonel Ochoa-Bayona, Farhad Khimani, Kelly Walton, Ryan Bookout, Michael Nieder, Divis K Khaira, Marco Davila, Melissa Alsina, Teresa Field, Ernesto Ayala, Frederick L Locke, Marcie Riches, Mohamed Kharfan-Dabaja, Hugo Fernandez, Claudio Anasetti,

Graft-versus-host disease (GvHD) remains a major cause of transplant-related mortality. Interleukin-2 (IL-2) plus sirolimus (SIR) synergistically reduces acute GvHD in rodents and promotes regulatory T cells. This phase II trial tested the hypothesis that IL-2 would facilitate STAT5 phosphorylation in donor T cells, expand regulatory T cells, and ameliorate GvHD. ... Read more >>

Haematologica (Haematologica)
[2017, 102(5):948-957]

Cited: 9 times

View full text PDF listing >>



Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.

Brian C Betts, Anandharaman Veerapathran, Joseph Pidala, Hua Yang, Pedro Horna, Kelly Walton, Christopher L Cubitt, Steven Gunawan, Harshani R Lawrence, Nicholas J Lawrence, Said M Sebti, Claudio Anasetti,

Graft-versus-host disease (GVHD) is a leading cause of nonrelapse mortality after allogeneic hematopoietic cell transplantation. T cell costimulation by CD28 contributes to GVHD, but prevention is incomplete when targeting CD28, downstream mammalian target of rapamycin (mTOR), or Aurora A. Likewise, interleukin-6 (IL-6)-mediated Janus kinase 2 (JAK2) signaling promotes alloreactivity, yet ... Read more >>

Sci Transl Med (Science translational medicine)
[2017, 9(372):]

Cited: 13 times

View full text PDF listing >>



Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.

Shane A Curran, Justin A Shyer, Erin T St Angelo, Lillian R Talbot, Sneh Sharma, David J Chung, Glenn Heller, Katharine C Hsu, Brian C Betts, James W Young,

Janus kinase (JAK) inhibitors have achieved positive responses in myeloproliferative neoplasms, but at the expense of decreased natural killer (NK) cell numbers and compromised function. Selective JAK2 inhibition may also have a role in preventing and treating graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Although JAK inhibitors can impair ... Read more >>

Cancer Immunol Res (Cancer immunology research)
[2017, 5(1):52-60]

Cited: 9 times

View full text PDF listing >>



Tolerance associated gene expression following allogeneic hematopoietic cell transplantation.

Joseph Pidala, Gregory C Bloom, Steven Eschrich, Minnie Sarwal, Steve Enkemann, Brian C Betts, Francisca Beato, Sean Yoder, Claudio Anasetti,

Biologic markers of immune tolerance may facilitate tailoring of immune suppression duration after allogeneic hematopoietic cell transplantation (HCT). In a cross-sectional study, peripheral blood samples were obtained from tolerant (n = 15, median 38.5 months post-HCT) and non-tolerant (n = 17, median 39.5 post-HCT) HCT recipients and healthy control subjects ... Read more >>

PLoS One (PloS one)
[2015, 10(3):e0117001]

Cited: 4 times

View full text PDF listing >>



Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.

Joseph Pidala, Jongphil Kim, Melissa Alsina, Ernesto Ayala, Brian C Betts, Hugo F Fernandez, Teresa Field, Heather Jim, Mohamed A Kharfan-Dabaja, Frederick L Locke, Asmita Mishra, Taiga Nishihori, Leonel Ochoa-Bayona, Lia Perez, Marcie Riches, Claudio Anasetti,

Effective pharmacological strategies employed in allogeneic hematopoietic cell transplantation should prevent serious chronic graft-versus-host disease and facilitate donor-recipient immune tolerance. Based on demonstrated pro-tolerogenic activity, sirolimus (rapamycin) is an agent with promise to achieve these goals. In a long-term follow-up analysis of a randomized phase II trial comparing sirolimus/tacrolimus versus ... Read more >>

Haematologica (Haematologica)
[2015, 100(7):970-977]

Cited: 10 times

View full text PDF listing >>



CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.

Brian C Betts, Elizabeth M Sagatys, Anandharaman Veerapathran, Mark C Lloyd, Francisca Beato, Harshani R Lawrence, Binglin Yue, Jongphil Kim, Said M Sebti, Claudio Anasetti, Joseph Pidala,

Th17 cells contribute to severe GVHD in murine bone marrow transplantation. Targeted deletion of the RORγt transcription factor or blockade of the JAK2-STAT3 axis suppresses IL-17 production and alloreactivity by Th17 cells. Here, we show that pSTAT3 Y705 is increased significantly in CD4(+) T cells among human recipients of allogeneic ... Read more >>

J. Leukoc. Biol. (Journal of leukocyte biology)
[2015, 97(4):807-819]

Cited: 25 times

View full text PDF listing >>



Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.

Joseph Pidala, Jongphil Kim, Brian C Betts, Melissa Alsina, Ernesto Ayala, Hugo F Fernandez, Teresa Field, Mohamed A Kharfan-Dabaja, Frederick L Locke, Asmita Mishra, Taiga Nishihori, Leonel Ochoa-Bayona, Lia Perez, Marcie Riches, Claudio Anasetti,

Standard primary therapy for chronic graft-versus-host disease (GVHD) is incompletely effective. Based on biologic insights implicating pathogenic B cells, we conducted a phase I trial examining the combination of standard (1 mg/kg/day prednisone) glucocorticoid therapy with ofatumumab, a humanized anti-CD20 monoclonal antibody, for primary chronic GVHD therapy. Patients ages ≥ ... Read more >>

Biol Blood Marrow Transplant (Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation)
[2015, 21(6):1074-1082]

Cited: 9 times

View full text PDF listing >>



STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity.

Brian C Betts, Anandharaman Veerapathran, Joseph Pidala, Xue-Zhong Yu, Claudio Anasetti,

Alloreactivity negatively influences outcomes of organ transplantation or HCT from allogeneic donors. Standard pharmacologic immune suppression impairs T-cell function and jeopardizes the beneficial reconstitution of Tregs. Murine transplantation models have shown that STAT3 is highly expressed in alloreactive T cells and may be therapeutically targeted. The influence and effects of ... Read more >>

J. Leukoc. Biol. (Journal of leukocyte biology)
[2014, 95(2):205-213]

Cited: 16 times

View full text PDF listing >>



A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.

Joseph Pidala, Jongphil Kim, Heather Jim, Mohamed A Kharfan-Dabaja, Taiga Nishihori, Hugo F Fernandez, Marcie Tomblyn, Lia Perez, Janelle Perkins, Mian Xu, William E Janssen, Anandaraman Veerapathran, Brian C Betts, Frederick L Locke, Ernesto Ayala, Teresa Field, Leonel Ochoa, Melissa Alsina, Claudio Anasetti,

There is evidence suggesting that sirolimus, in combination with tacrolimus, is active in the prevention of graft-versus-host disease. Sirolimus-based immune suppression may suppress alloreactive T cells, while sparing the survival and function of regulatory T cells.We conducted a randomized trial to compare the impact of sirolimus/tacrolimus against that of methotrexate/tacrolimus ... Read more >>

Haematologica (Haematologica)
[2012, 97(12):1882-1889]

Cited: 50 times

View full text PDF listing >>



Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.

Brian C Betts, Erin T St Angelo, Michael Kennedy, James W Young,

Significant comorbidites and lethality complicate GVHD and its treatment. Targeting the cytokine milieu may improve GVHD control; and IL6 is an attractive candidate, given its role in dendritic cell activation and T-cell differentiation. Tocilizumab is a humanized mAb to IL6-receptor-α (IL6R-α), which is Food and Drug Administration-approved for treatment of ... Read more >>

Blood (Blood)
[2011, 118(19):5340-5343]

Cited: 25 times

View full text PDF listing >>



Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.

Emanuela Romano, Jesse W Cotari, Rosa Barreira da Silva, Brian C Betts, David J Chung, Francesca Avogadri, Mitsu J Fink, Erin T St Angelo, Babak Mehrara, Glenn Heller, Christian Münz, Gregoire Altan-Bonnet, James W Young,

Human CD34(+) progenitor-derived Langerhans-type dendritic cells (LCs) are more potent stimulators of T-cell immunity against tumor and viral antigens in vitro than are monocyte-derived DCs (moDCs). The exact mechanisms have remained elusive until now, however. LCs synthesize the highest amounts of IL-15R-α mRNA and protein, which binds IL-15 for presentation ... Read more >>

Blood (Blood)
[2012, 119(22):5182-5190]

Cited: 31 times

View full text PDF listing >>



Advertisement

Disclaimer
1.3167 s